Similar articles

• [TNF targetting therapy for rheumatoid arthritis].

  Takeuchi T. Takeuchi T. Nihon Naika Gakkai Zasshi. 2006 Sep 10;95(9):1787-94. doi: 10.2169/naika.95.1787. Nihon Naika Gakkai Zasshi. 2006. PMID: 17037316 Review. Japanese. No abstract available.
• Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.

  Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A. Dewedar AM, et al. Int J Rheum Dis. 2012 Jun;15(3):330-5. doi: 10.1111/j.1756-185X.2012.01715.x. Epub 2012 Feb 13. Int J Rheum Dis. 2012. PMID: 22709496
• Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.

  Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA. Markatseli TE, et al. Clin Exp Rheumatol. 2012 Jan-Feb;30(1):31-8. Epub 2012 Mar 6. Clin Exp Rheumatol. 2012. PMID: 22153557
• Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis.

  Titos Arcos JC, Hallal H, Robles M, Andrade RJ. Titos Arcos JC, et al. Rev Esp Enferm Dig. 2012 May;104(5):282-4. doi: 10.4321/s1130-01082012000500014. Rev Esp Enferm Dig. 2012. PMID: 22662786 No abstract available.
• TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.

  Williams VL, Cohen PR. Williams VL, et al. Int J Dermatol. 2011 May;50(5):619-25. doi: 10.1111/j.1365-4632.2011.04871.x. Int J Dermatol. 2011. PMID: 21506984 Review.